Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $25.1B | $6.3B | $3.2B | $4.3B | 14.5% | 11.2% | 8.5% |
| 2024 | $22.6B | $5.0B | $3.0B | $3.5B | 14.5% | 10.2% | -5.4% |
| 2023 | $20.5B | $5.1B | $3.2B | $3.1B | 17.0% | 11.1% | 34.2% |
| 2022 | $18.4B | $4.1B | $2.4B | $2.0B | 14.2% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 18,449 | 20,498 | 22,595 | 25,116 |
| Operating Revenue | - | 18,449 | 20,498 | 22,595 | 25,116 |
| Cost Of Revenue | - | 6,871 | 7,440 | 8,155 | 9,051 |
| Gross Profit | - | 11,578 | 13,058 | 14,440 | 16,065 |
| Operating Expense | - | 8,467 | 9,134 | 9,774 | 11,006 |
| Research And Development | - | 1,454 | 1,388 | 1,466 | 1,623 |
| Selling General And Administration | - | 6,386 | 7,111 | 7,685 | 8,651 |
| Total Expenses | - | 15,338 | 16,574 | 17,929 | 20,057 |
| Operating Income | - | 3,111 | 3,924 | 4,666 | 5,059 |
| Total Operating Income As Reported | - | 2,841 | 3,888 | 3,689 | 4,889 |
| EBITDA | - | 4,109 | 5,064 | 4,951 | 6,314 |
| Normalized EBITDA | - | 4,379 | 5,100 | 5,928 | 6,484 |
| EBIT | - | 3,111 | 4,036 | 3,901 | 5,121 |
| Interest Expense | - | - | 363 | 409 | 607 |
| Net Interest Income | - | - | -363 | -409 | -607 |
| Other Non Operating Income Expenses | - | -158 | 148 | 212 | 232 |
| Other Income Expense | - | -428 | 112 | -765 | 62 |
| Interest Expense Non Operating | - | - | 363 | 409 | 607 |
| Net Non Operating Interest Income Expense | - | - | -363 | -409 | -607 |
| Pretax Income | - | 2,683 | 3,673 | 3,492 | 4,514 |
| Tax Provision | - | 325 | 508 | 499 | 1,268 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -32.67 | -4.97 | -139.61 | -47.75 |
| Net Income Continuous Operations | - | 2,358 | 3,165 | 2,993 | 3,246 |
| Net Income From Continuing And Discontinued Operation | - | 2,358 | 3,165 | 2,993 | 3,246 |
| Net Income From Continuing Operation Net Minority Interest | - | 2,358 | 3,165 | 2,993 | 3,246 |
| Net Income | - | 2,358 | 3,165 | 2,993 | 3,246 |
| Net Income Common Stockholders | - | 2,358 | 3,165 | 2,993 | 3,246 |
| Net Income Including Noncontrolling Interests | - | 2,358 | 3,165 | 2,993 | 3,246 |
| Normalized Income | - | 2,595.33 | 3,196.03 | 3,830.39 | 3,368.25 |
| Diluted NI Availto Com Stockholders | - | 2,358 | 3,165 | 2,993 | 3,246 |
| Basic Average Shares | - | 378.20 | 379.60 | 381 | 382.20 |
| Diluted Average Shares | - | 382.20 | 383.70 | 385.60 | 386.50 |
| Reconciled Depreciation | - | 998 | 1,028 | 1,050 | 1,193 |
| Reconciled Cost Of Revenue | - | 6,500 | 7,047 | 7,728 | 8,590 |
| Total Unusual Items | - | -270 | -36 | -977 | -170 |
| Total Unusual Items Excluding Goodwill | - | -270 | -36 | -977 | -170 |
| Special Income Charges | - | -270 | -36 | -977 | -170 |
| Other Special Charges | 103 | -15 | 18 | - | - |
| Impairment Of Capital Assets | - | 270 | 36 | 977 | 170 |
| Depreciation Amortization Depletion Income Statement | - | 627 | 635 | 623 | 732 |
| Depreciation And Amortization In Income Statement | - | 627 | 635 | 623 | 732 |
| Amortization | - | 627 | 635 | 623 | 732 |
| Amortization Of Intangibles Income Statement | - | 627 | 635 | 623 | 732 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Stryker Corporationthis co. | SYK | $115.5B | 35.57↑ premium | 5.15 | 14.5% | 20.16 |
| Pfizer Inc. | PFE | $146.4B | 18.84 | 1.69 | 9.0% | 12.47 |
| Danaher Corporation | DHR | $132.1B | 36.55 | 2.51 | 6.9% | 21.19 |
| CVS Health Corporation | CVS | $121.0B | 68.43 | 1.61 | 2.4% | 19.52 |
| Bristol-Myers Squibb Company | BMY | $115.6B |
| - |
| - |
| - |
| - |
| - |
| 16.39 |
| 6.26 |
| 38.2% |
| 10.01 |
| Vertex Pharmaceuticals Incorporated | VRTX | $112.1B | 28.36 | 6.01 | 21.2% | 22.41 |
| Medtronic plc | MDT | $105.2B | 22.56 | 2.19 | 9.7% | 14.26 |
| McKesson Corporation | MCK | $91.0B | 19.11 | -41.89 | -219.2% | 13.32 |
| Elevance Health, Inc. | ELV | $88.9B | 15.70 | 2.03 | 12.9% | - |
| Peer Median | - | 20.84 | 2.11 | 9.3% | 14.26 | |
Historically, Jan has averaged the highest return (+4.5%); Sep the lowest (-3.0%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +5.1%Positive MonthJan 2026: +5.15% | +4.8%Positive MonthFeb 2026: +4.84% | -15.2%Negative MonthMar 2026: -15.19% | -4.1%Negative MonthApr 2026: -4.10% | -3.2%Negative MonthMay 2026: -3.19% | +3.2%Positive MonthJun 2026: +3.20% | +3.4%Positive MonthJul 2026: +3.45% | +4.4%*Positive MonthAug 2026: +4.38% | — | — | — | — |
| 2025 | +8.7%Positive MonthJan 2025: +8.68% | -1.3%Neutral MonthFeb 2025: -1.30% | -3.6%Negative MonthMar 2025: -3.61% | +0.4%Neutral MonthApr 2025: +0.45% | +2.3%Positive MonthMay 2025: +2.33% | +3.4%Positive MonthJun 2025: +3.39% | -0.7%Neutral MonthJul 2025: -0.73% | -0.3%Neutral MonthAug 2025: -0.34% | -5.6%Negative MonthSep 2025: -5.55% | -3.6%Negative MonthOct 2025: -3.63% | +4.2%Positive MonthNov 2025: +4.19% | -5.3%Negative MonthDec 2025: -5.31% |
| 2024 | +12.0%Positive MonthJan 2024: +12.03% | +4.1%Positive MonthFeb 2024: +4.05% | +2.5%Positive MonthMar 2024: +2.52% | -6.0%Negative MonthApr 2024: -5.97% | +1.4%Neutral MonthMay 2024: +1.36% | -0.2%Neutral MonthJun 2024: -0.25% | -3.8%Negative MonthJul 2024: -3.76% | +10.1%Positive MonthAug 2024: +10.07% | +0.2%Neutral MonthSep 2024: +0.23% | -1.4%Neutral MonthOct 2024: -1.38% | +10.1%Positive MonthNov 2024: +10.07% | -8.2%Negative MonthDec 2024: -8.19% |
| 2023 | +3.8%Positive MonthJan 2023: +3.81% | +3.6%Positive MonthFeb 2023: +3.57% | +8.6%Positive MonthMar 2023: +8.59% | +5.0%Positive MonthApr 2023: +4.97% | -8.0%Negative MonthMay 2023: -8.03% | +10.7%Positive MonthJun 2023: +10.71% | -7.1%Negative MonthJul 2023: -7.11% | +0.0%Neutral MonthAug 2023: +0.05% | -3.6%Negative MonthSep 2023: -3.63% | -1.1%Neutral MonthOct 2023: -1.12% | +9.7%Positive MonthNov 2023: +9.66% | +1.1%Neutral MonthDec 2023: +1.06% |
| 2022 | -7.2%Negative MonthJan 2022: -7.24% | +6.2%Positive MonthFeb 2022: +6.17% | +1.5%Neutral MonthMar 2022: +1.52% | -9.8%Negative MonthApr 2022: -9.76% | -2.8%Negative MonthMay 2022: -2.80% | -15.2%Negative MonthJun 2022: -15.17% | +8.0%Positive MonthJul 2022: +7.95% | -4.4%Negative MonthAug 2022: -4.45% | -1.3%Neutral MonthSep 2022: -1.30% | +13.2%Positive MonthOct 2022: +13.18% | +2.0%Positive MonthNov 2022: +2.03% | +4.5%Positive MonthDec 2022: +4.53% |
| 2021 | — | — | — | — | -2.8%Negative MonthMay 2021: -2.80% | +1.7%Neutral MonthJun 2021: +1.75% | +4.3%Positive MonthJul 2021: +4.32% | +2.3%Positive MonthAug 2021: +2.27% | -4.8%Negative MonthSep 2021: -4.83% | +0.9%Neutral MonthOct 2021: +0.89% | -11.1%Negative MonthNov 2021: -11.06% | +13.0%Positive MonthDec 2021: +13.01% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
